English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

We thank Dr. Kashani and Dr. Abadi [1] for their interest in our article [2]. In Japan, seven-day vonoprazan-containing triple therapy with clarithromycin and amoxicillin or vonoprazan-containing triple therapy with metronidazole and amoxicillin are approved regimens [3], but vonoprazancontaining triple therapy with clarithromycin and metronidazole is not approved and is used only in clinical trials which was approved by the ethics committee. Thus, people who cannot be given the standard triple therapy due to being allergic to penicillin are the subjects of this study. In addition, these patients cannot be covered by their medical insurance system for Helicobacter pylori eradication and related examinations, so it is difficult to add antibiotic susceptibility testing after the diagnosis of H. pylori infection for cost and ethical reason (this study was not designed to choose regimen by antibiotic resistance result). About the sample size, as we have also written the reason is the rate of patients allergic to penicillin, which makes it difficult to recruit many patients for this type of study. These are the explanations overall. We also answer each question: (i) Generalization of the finding: We think the efficacy of this regimen is influenced by metronidazole resistance rates. In Japan, the metronidazole resistance rate is not high, and it is reported that metronidazole-containing triple therapy as a firstline therapy showed high eradication rate (ER) [4]. It is an important point that the vonoprazan, clarithromycin, and metronidazole regimen demonstrated excellent ER in areas with a high rate of clarithromycin resistance in two studies [2, 5], but these were performed in a country with a low rate of metronidazole resistance compared to other countries. We hope this regimen will be useful in countries with high clarithromycin but low metronidazole resistance rates as eradication regimen for those allergic to penicillin instead of PPI-based triple therapy with clarithromycin and metronidazole.

gastroenterology research and practice

Response to: Comment on “First-Line <i>Helicobacter pylori</i> Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin”

Response to: Comment on “First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin”